Skip to main content
TrendingNews.today
World News
S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|
S&P 500 5,142.30 ▲ +0.87%|NASDAQ 16,284.75 ▲ +1.12%|DOW 38,972.10 ▼ -0.23%|AAPL $192.45 ▲ +1.80%|TSLA $241.80 ▼ -2.10%|AMZN $178.92 ▲ +0.54%|GOOGL $141.20 ▲ +0.32%|MSFT $415.60 ▼ -0.15%|
As of Mar 25
ScienceUnited States1 sourcesNeutral

Karyopharm phase III Sentry entry bucks rux in MF; to FDA next

What one analyst called an “intriguing” overall survival signal in phase III results has Karyopharm Therapeutics Inc. planning to meet with the U.S. FDA about a would-be sNDA filing for Xpovio (selinexor) in myelofibrosis (MF).

RO
randy osborne
via Bioworld
ShareRead original

Read the full article at Bioworld →

Karyopharm phase III Sentry entry bucks rux in MF; to FDA next

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

Bioworld
Bioworld
NewsDataUS

Comments

0 comments
Be respectful and constructive.
Loading comments...
Previous
What time is Senate vote today on shutdown 2026? Next vote, DHS news
Next
Iran War: Is the New Zealand economy cooked?

Related Articles

This pinot noir hasn’t changed in 500 yearsScience
This pinot noir hasn’t changed in 500 years
Popular Science-13h ago-1 sources
Gilead pens dual-purpose $2B Ouro M&A deal with GalapagosScience
Gilead pens dual-purpose $2B Ouro M&A deal with Galapagos
Bioworld-13h ago-1 sources
China’s pharma rise rattles US policymakersScience
China’s pharma rise rattles US policymakers
Bioworld-13h ago-1 sources